Clinical Trials Browser

Vorinostat × Dermatologic × 90 days × Clear all

NCT02943642 2026-05-18

Resimmune®

Phase 2 Withdrawn

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT01587352 2026-04-13

Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

Phase 2 Active not recruiting

Uveal Melanoma